MFMarcel Flendrie

Marcel Flendrie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcel Flendrie has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Text Messaging Between Patients With Inflammatory Rheumatic Diseases and Pharmacists to Solve Drug-Related Problems: Prospective Feasibility Study

    by Lex L Haegens, Charlotte L Bekker, Marcel Flendrie, Bart J F van Den Bemt, Victor J B Huiskes

    Background: Patients with inflammatory rheumatic diseases often experience drug-related problems (DRPs). As these can result in negative health consequences, DRPs should be identified and addressed in a timely manner. Text messaging between patients and pharmacists at the initiative of the patient has the potential to deliver support with DRPs more continuously, increase accessibility and efficiency, and enhance patient involvement in the process of identifying and solving DRPs. Objective: This study aimed to assess the feasibility of text messaging from both the patients’ and health care practitioners’ perspectives before a large-scale implementation. Methods: Adult patients using a disease-modifying antirheumatic drug were given access to text messaging with pharmacists to discuss DRPs for a period of 8 weeks. Patients received a response from a pharmacist within 4 working hours. Feasibility was evaluated based on five domains of Bowen’s framework for designing feasibility studies: (1) demand: actual use, expressed interest (user version of the Mobile Application Rating Scale – section E), and factors impacting future use; (2) limited efficacy: number of DRPs solved, DRPs resulting in follow-up, and DRPs warranting involvement of health care provider; (3) implementation: degree of execution (number of conversations answered within service level) and resources needed (pharmacists’ time investment per conversation); (4) acceptability: satisfaction and appropriateness (theoretical framework of acceptability); and (5) practicality: ability to carry out intervention activities (System Usability Scale). Data were collected by means of usage data and a questionnaire. Results: In total, 45 patients (median age 57, IQR 52-65 y; n=31, 69% female) and 5 pharmacists (median age 41, IQR 26-47 y; n=1, 20% female) actively participated in this study. In the demand domain, 158 unique DRPs were raised in 133 conversations, with a median of 3 (IQR 2-4) unique DRPs per patient. Expressed interest was rated high by patients (median 4, IQR 4-5), and 90% (37/41) of patients would recommend text messaging to others. In the limited-efficacy domain, all DRPs were solved, and 77% (122/158) of DRPs warranted involvement of a health care provider. In the implementation domain, 87% (116/133) of conversations were answered within the promised timeframe with a median time investment of 4:15 (IQR 2:21-7:27) minutes per conversation. Acceptability was rated high by patients (median 4, IQR 4-5) and pharmacists (median 5, IQR 4-5). Finally, in the practicality domain, System Usability Scale was scored above average for patients (mean 72, SD 18) and pharmacists (mean 81, SD 16). Conclusion: Text messaging with pharmacists at the initiative of patients with rheumatic diseases seems feasible for discussing DRPs in terms of limited efficacy, implementation, acceptability, demand, and practicality for patients and pharmacists.

  • Similar gout flare incidence rates when using once- or twice-daily 0.5 mg colchicine prophylaxis after the start of xanthine oxidase inhibitors

    by L Nieboer, F Veenstra, L Verhoef, Aa Den Broeder, Wy Kwok, N van Herwaarden, M Flendrie

    To investigate the potential superiority of colchicine prophylaxis twice daily over once daily in preventing gout flares in the first 6 months after initiating xanthine oxidase inhibitors (XOIs). A retrospective cohort study was conducted in three rheumatology centres in the Netherlands. Gout flare incidence densities were calculated for patients using colchicine once or twice daily in the first 6 months after starting XOIs. The incidence rate ratios (IRRs) between groups were analysed using Poisson regression, adjusted for confounders. The proportion of patients reaching a serum urate of <0.36 mmol/L within the first 6 months was compared between groups. In total, 808 gout patients started XOIs (allopurinol in 99.7%) with colchicine prophylaxis: 192 on twice-daily and 616 on once-daily colchicine 0.5 mg. The incidence densities of gout flares were 3.3 and 2.8 per patient-year, resulting in an IRR of 0.93 [95% confidence interval (CI) 0.80-1.09] for twice-daily compared to once-daily colchicine, adjusted for renal function (estimated glomerular filtration rate), serum urate at baseline, duration of colchicine prophylaxis, C-reactive protein, age, duration of illness, fast dose titration, tophi, gouty bone erosions, and monosodium urate crystal confirmation. Within 6 months, 59.8% and 68.6% in the colchicine twice-daily and once-daily groups, respectively, reached the serum urate target (difference -8.8%, 95% CI 1.1% to -18.7%). Colchicine prophylaxis 0.5 mg twice daily was not superior to colchicine once daily regarding flare prophylaxis after starting an XOI. As colchicine twice daily is associated with higher intolerability and costs, once-daily dosing should be preferred.


  • Open Access

    Can Urate Lowering Therapy Be Stopped in Gout? Rationale and Design of Two Large Randomised Trials

    by Pascal Richette, Marcel Flendrie, Leo A. B. Joosten, Noortje van Herwaarden

    Lifelong urate-lowering therapy (ULT) is recommended for gout to prevent flares and urate deposition. However, concerns about its adherence, long-term side effects, and the necessity of continuous treatment after achieving remission raise critical questions. Two randomised controlled trials (RCTs), GO TEST Finale and STING, aim to evaluate the safety and feasibility of ULT discontinuation in gout patients in remission. The GO TEST Finale is a superiority trial involving 310 patients in the Netherlands, comparing a treat-to-target (T2T) ULT continuation strategy with ULT discontinuation. Patients in the discontinuation arm resume ULT only after flare recurrence or tophi development. The primary outcomes focus on remission criteria failure over 24 months, while the secondary outcomes explore predictors of successful discontinuation and cost-effectiveness. The STING study, a non-inferiority trial in France, includes 450 patients without ultrasound (US) evidence of urate deposits. Patients in the discontinuation group resume ULT if a US detects urate deposition during follow-up, minimising flare risk. The primary outcomes measure the proportion of patients experiencing flares at two years, with the secondary outcomes examining the long-term health impacts and cost-effectiveness. These trials provide an opportunity for translational research into the immunological and epigenetic effects of rising serum urate levels. The results could inform personalised strategies for a drug-free period and address the critical question of whether lifelong ULT is necessary for gout management. The complementary findings from both trials are expected to contribute significantly to resolving this ongoing clinical debate.


  • Open Access

    Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial

    by Iris Rose Peeters, Alfons A. Den Broeder, William J Taylor, Nathan Den Broeder, Marcel Flendrie, Noortje van Herwaarden

    Background: Long-term gout treatment is based on reducing serum urate levels using urate-lowering therapy (ULT). Most guidelines recommend using a lifelong continuation treat-to-target (T2T) strategy, in which ULT is dosed or combined until a serum urate target has been reached and maintained. However, a frequently used alternative strategy in clinical practice is a treat-to-avoid-symptoms (T2S) ULT discontinuation strategy, with the possibility of restarting the medication. This latter strategy aims at an acceptable symptom state, regardless of serum urate levels. High-quality evidence to support either strategy for patients in prolonged remission while using ULT is lacking. Methods: We developed an investigator-driven pragmatic, open-label, multicentre, randomized, superiority treatment strategy trial (GO TEST Finale). At least 278 gout patients using ULT who are in remission (>12 months, preliminary gout remission criteria) will be randomized 1:1 to a continued T2T strategy (treatment target serum urate < 0.36 mmol/l) or switched to a T2S discontinuation strategy in which ULT is tapered to stop and restarted in case of (persistent or recurrent) flaring. The primary outcome is the between-group difference in the proportion of patients not in remission during the last 6 months of 24 months follow-up and will be analyzed using a two proportion z test. Secondary outcomes are group differences in gout flare incidence, reintroduction or adaptation of ULT, use of anti-inflammatory drugs, serum urate changes, occurrence of adverse events (with a special interest in cardiovascular and renal events), and cost-effectiveness. Discussion: This study will be the first clinical trial comparing two ULT treatment strategies in patients with gout in remission. It will contribute to more specific and unambiguous guideline recommendations and improved cost-effectiveness of long-term gout treatment. It also paves the way (exploratory) to individualized long-term ULT treatment. In this article, we elaborate on some of our trial design choices and their clinical and methodological consequences. Trial registration: International Clinical Trial Registry Platform (ICTRP) NL9245. Registered on 2 February 2021 (METC Oost-Nederland NL74350.091.20); EudraCT EUCTR2020-005730-15-NL. Registered on 11 January 2021.